Aviva PLC reduced its holdings in shares of HCP, Inc. (NYSE:HCP) by 3.6% in the third quarter, Holdings Channel reports. The institutional investor owned 227,838 shares of the real estate investment trust’s stock after selling 8,496 shares during the period. Aviva PLC’s holdings in HCP were worth $5,997,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Mount Yale Investment Advisors LLC purchased a new stake in HCP during the second quarter valued at approximately $104,000. Piedmont Investment Advisors LLC purchased a new stake in HCP during the second quarter valued at approximately $142,000. Peoples Financial Services CORP. increased its holdings in HCP by 87.7% during the third quarter. Peoples Financial Services CORP. now owns 6,100 shares of the real estate investment trust’s stock valued at $161,000 after buying an additional 2,850 shares during the last quarter. Wetherby Asset Management Inc. purchased a new stake in HCP during the third quarter valued at approximately $200,000. Finally, Lourd Capital LLC purchased a new stake in HCP during the third quarter valued at approximately $211,000. 90.00% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE HCP opened at $30.23 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.48 and a quick ratio of 0.48. The firm has a market capitalization of $13.67 billion, a PE ratio of 15.50, a PEG ratio of 7.33 and a beta of 0.23. HCP, Inc. has a 1 year low of $21.48 and a 1 year high of $30.26.

HCP (NYSE:HCP) last announced its quarterly earnings data on Wednesday, October 31st. The real estate investment trust reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.10. HCP had a net margin of 9.16% and a return on equity of 3.06%. The firm had revenue of $456.00 million during the quarter, compared to analysts’ expectations of $456.59 million. During the same period in the prior year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up .4% compared to the same quarter last year. As a group, research analysts predict that HCP, Inc. will post 1.82 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, November 20th. Investors of record on Monday, November 5th were given a dividend of $0.37 per share. The ex-dividend date was Friday, November 2nd. This represents a $1.48 dividend on an annualized basis and a dividend yield of 4.90%. HCP’s dividend payout ratio is 75.90%.

In related news, COO Thomas Klaritch sold 82,532 shares of the company’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $29.51, for a total transaction of $2,435,519.32. Following the completion of the transaction, the chief operating officer now owns 256,280 shares in the company, valued at $7,562,822.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.14% of the stock is currently owned by corporate insiders.

A number of analysts have recently issued reports on the stock. Zacks Investment Research reissued a “sell” rating on shares of HCP in a research note on Tuesday, November 13th. ValuEngine raised shares of HCP from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Royal Bank of Canada raised shares of HCP from a “sector perform” rating to an “outperform” rating in a research note on Friday, November 2nd. Cantor Fitzgerald increased their price objective on shares of HCP from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 1st. Finally, BMO Capital Markets reissued a “hold” rating and issued a $27.00 price objective on shares of HCP in a research note on Wednesday, October 31st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $26.75.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/aviva-plc-trims-holdings-in-hcp-inc-hcp/2666488.html.

HCP Company Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Featured Story: Trading Penny Stocks

Want to see what other hedge funds are holding HCP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCP, Inc. (NYSE:HCP).

Institutional Ownership by Quarter for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.